Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bavarian Nordic A/S (BVNRY)
:BVNRY
Holding BVNRY?
Track your performance easily
BVNRY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.90 - $13.92
Previous CloseN/A
Volume6.49K
Average Volume (3M)12.79K
Market Cap
$2.11B
Enterprise Value$2.45B
Total Cash (Recent Filing)$1.91B
Total Debt (Recent Filing)$29.71M
Price to Earnings (P/E)12.9
Beta1.39
Next Earnings
Mar 05, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 27, 2020Dividend YieldN/A
Share Statistics
EPS (TTM)0.70
Shares Outstanding236,501,310
10 Day Avg. Volume7,276
30 Day Avg. Volume12,791
Standard Deviation0.18
R-Squared0.22
Alpha-0.00044
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.21
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue0.78
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda10.69
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bavarian Nordic News
PremiumCompany Announcements
Bavarian Nordic Reports Strong Travel Health Growth in 2024
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.02%
Mutual Funds
0.01% Other Institutional Investors
99.97% Public Companies and Individual Investors
BVNRY FAQ
What was Bavarian Nordic A/S’s price range in the past 12 months?
Bavarian Nordic A/S lowest stock price was $6.90 and its highest was $13.92 in the past 12 months.
What is Bavarian Nordic A/S’s market cap?
Bavarian Nordic A/S’s market cap is $2.11B.
When is Bavarian Nordic A/S’s upcoming earnings report date?
Bavarian Nordic A/S’s upcoming earnings report date is Mar 05, 2025 which is in 45 days.
How were Bavarian Nordic A/S’s earnings last quarter?
Bavarian Nordic A/S released its earnings results on Nov 15, 2024. The company reported $0.044 earnings per share for the quarter, beating the consensus estimate of N/A by $0.044.
Is Bavarian Nordic A/S overvalued?
According to Wall Street analysts Bavarian Nordic A/S’s price is currently Overvalued.
Does Bavarian Nordic A/S pay dividends?
Bavarian Nordic A/S pays a Notavailable dividend of $0.425 which represents an annual dividend yield of N/A. See more information on Bavarian Nordic A/S dividends here
What is Bavarian Nordic A/S’s EPS estimate?
Bavarian Nordic A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bavarian Nordic A/S have?
Bavarian Nordic A/S has 236,501,310 shares outstanding.
What happened to Bavarian Nordic A/S’s price movement after its last earnings report?
Bavarian Nordic A/S reported an EPS of $0.044 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -17.769%.
Which hedge fund is a major shareholder of Bavarian Nordic A/S?
Currently, no hedge funds are holding shares in BVNRY
---
Bavarian Nordic Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
BVNRY Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.83%
12-Months-Change
Fundamentals
Return on Equity
11.03%
Trailing 12-Months
Asset Growth
9.77%
Trailing 12-Months
Company Description
Bavarian Nordic A/S
Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.
---
BVNRY Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in the Travel Health portfolio and Public Preparedness, with record orders for the coming year. However, there are challenges with specific vaccines and logistical issues impacting immediate revenue. The sentiment leans positive due to significant achievements and future prospects.Read More>---
Technical Analysis
---